About SAGE Therapeutics

SAGE is a neuroscience-focused company discovering medicines to treat life-threatening, rare CNS disorders. Launched in 2010, SAGE is a publicly traded company led by an experienced team of leaders, CNS experts and investors. Our lead program, SAGE-547, is in clinical development for super-refractory status epilepticus (SRSE) and is the first of many – more... 

Claimed Profile
215 First Street
Cambridge, MA 02142
SAGE Therapeutics website